Diabetes is a huge threat to the world's health. More than 330 million people around the world are estimated to have suffered from the disease in 2011, and more than 550 million are expected to suffer from it by 2030. However, where there's a big problem, big pharma has a big solution. For Merck (NYSE:MRK)Sanofi (NYSE:SNY), and Novo Nordisk (NYSE:NVO), treating diabetes has become a cash-generating windfall.

These three companies boast three of the top drugs for treating diabetes around the world, from Merck's strong Januvia to Sanofi's timeless Lantus. However, patent expirations and tough competition are making the diabetes field as competitive a market as any in big pharma. How will these three giants fare in the next 10 years for treating the world's fastest-growing health crisis?

In the video below, Fool contributor Dan Carroll tells you how these three big pharma kings dominate diabetes treatment -- and how they're poised to continue their reigns for another decade to come.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.